Trade Accelerate Diagnostics, Inc. - AXDX CFD
Market information is presented
as of 2023-09-21
- Summary
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Accelerate Diagnostics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 4.50-19.50 |
| Average Volume (10 days) | 8,230.00 |
| Average Volume (3 months) | 567.05K |
| Market Cap | 97.13M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 9.98M |
| Revenue | 11.67M |
| EPS | -34.77 |
| Dividend (Yield %) | N/A |
| Beta | 1.18 |
| Next Earnings Date | Nov 13, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
Accelerate Diagnostics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, November 13, 2023 | ||
| Time (UTC) 10:59 | Country US
| Event Q3 2023 Accelerate Diagnostics Inc Earnings Release Q3 2023 Accelerate Diagnostics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 12.752 | 11.782 | 11.165 | 9.297 | 5.67 |
| Revenue | 12.752 | 11.782 | 11.165 | 9.297 | 5.67 |
| Total Operating Expense | 71.992 | 73.549 | 74.865 | 82.128 | 86.039 |
| Selling/General/Admin. Expenses, Total | 39.193 | 49.236 | 46.904 | 51.886 | 54.014 |
| Research & Development | 26.915 | 21.943 | 21.255 | 25.345 | 26.838 |
| Depreciation / Amortization | 2 | ||||
| Operating Income | -59.24 | -61.767 | -63.7 | -72.831 | -80.369 |
| Interest Income (Expense), Net Non-Operating | -3.103 | -15.87 | -14.443 | -11.571 | -7.718 |
| Net Income Before Taxes | -62.57 | -77.657 | -78.203 | -84.416 | -88.115 |
| Net Income After Taxes | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Net Income Before Extra. Items | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Net Income | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Income Available to Common Excl. Extra. Items | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Income Available to Common Incl. Extra. Items | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Diluted Net Income | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Diluted Weighted Average Shares | 8.2161 | 6.1727 | 5.601 | 5.4506 | 5.4494 |
| Diluted EPS Excluding Extraordinary Items | -7.60616 | -12.588 | -13.9632 | -15.4671 | -16.2084 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -7.8882 | -13.1454 | -13.9632 | -15.4671 | -16.2084 |
| Cost of Revenue, Total | 9.449 | 7.663 | 6.706 | 4.897 | 3.187 |
| Gross Profit | 3.303 | 4.119 | 4.459 | 4.4 | 2.483 |
| Other, Net | -0.227 | -0.02 | -0.06 | -0.014 | -0.028 |
| Unusual Expense (Income) | -3.565 | -5.293 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 2.921 | 2.812 | 2.972 | 2.96 | 3.861 |
| Revenue | 2.921 | 2.812 | 2.972 | 2.96 | 3.861 |
| Cost of Revenue, Total | 2.122 | 1.801 | 2.131 | 2.381 | 2.781 |
| Gross Profit | 0.799 | 1.011 | 0.841 | 0.579 | 1.08 |
| Total Operating Expense | 28.811 | 18.874 | 16.932 | 17.921 | 21.651 |
| Selling/General/Admin. Expenses, Total | 7.564 | 10.105 | 8.771 | 8.255 | 11.493 |
| Research & Development | 5.82 | 6.968 | 6.03 | 7.285 | 7.576 |
| Operating Income | -25.89 | -16.062 | -13.96 | -14.961 | -17.79 |
| Interest Income (Expense), Net Non-Operating | -6.729 | -0.778 | -0.705 | -0.886 | -0.626 |
| Other, Net | 0.04 | 0.045 | -0.021 | -0.049 | -0.107 |
| Net Income Before Taxes | -32.579 | -16.795 | -14.686 | -15.896 | -18.523 |
| Net Income After Taxes | -32.735 | -16.795 | -14.609 | -15.896 | -18.523 |
| Net Income Before Extra. Items | -32.735 | -16.795 | -14.609 | -15.896 | -18.523 |
| Net Income | -32.735 | -16.795 | -14.609 | -15.896 | -18.523 |
| Income Available to Common Excl. Extra. Items | -32.735 | -16.795 | -14.609 | -15.896 | -18.523 |
| Income Available to Common Incl. Extra. Items | -32.735 | -16.795 | -14.609 | -15.896 | -18.523 |
| Diluted Net Income | -32.735 | -16.795 | -14.609 | -15.896 | -18.523 |
| Diluted Weighted Average Shares | 1.1009 | 9.8301 | 9.7497 | 8.7011 | 7.6231 |
| Diluted EPS Excluding Extraordinary Items | -29.7348 | -1.70853 | -1.49841 | -1.8269 | -2.42985 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -21.8791 | -1.70853 | -1.49841 | -1.8269 | -2.45596 |
| Unusual Expense (Income) | 13.305 | 0 | 0 | 0 | -0.199 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 56.014 | 73.331 | 81.987 | 121.852 | 177.64 |
| Cash and Short Term Investments | 45.561 | 63.618 | 68.269 | 108.451 | 166.478 |
| Cash & Equivalents | 34.905 | 39.898 | 35.781 | 61.014 | 66.26 |
| Short Term Investments | 10.656 | 23.72 | 32.488 | 47.437 | 100.218 |
| Total Receivables, Net | 2.416 | 2.32 | 1.55 | 3.222 | 1.86 |
| Accounts Receivable - Trade, Net | 2.416 | 2.32 | 1.55 | 3.222 | 1.86 |
| Prepaid Expenses | 0.818 | 0.768 | 1.172 | 0.955 | 0.98 |
| Other Current Assets, Total | 2.025 | 1.558 | 1.78 | 1.165 | 0.576 |
| Total Assets | 65.015 | 83.047 | 93.425 | 134.424 | 185.265 |
| Property/Plant/Equipment, Total - Net | 7.759 | 7.899 | 9.318 | 11.822 | 7.303 |
| Property/Plant/Equipment, Total - Gross | 18.58 | 18.698 | 20.153 | 21.687 | 16.014 |
| Accumulated Depreciation, Total | -10.821 | -10.799 | -10.835 | -9.865 | -8.711 |
| Intangibles, Net | 0.114 | ||||
| Total Current Liabilities | 66.557 | 6.945 | 6.969 | 8.162 | 7.763 |
| Accounts Payable | 4.501 | 1.983 | 1.29 | 2.351 | 1.322 |
| Accrued Expenses | 3.983 | 4.431 | 4.75 | 5.54 | 6.224 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 57.526 | 0.08 | 0.553 | ||
| Other Current Liabilities, Total | 0.547 | 0.451 | 0.376 | 0.271 | 0.217 |
| Total Liabilities | 87.279 | 118.118 | 156.237 | 141.803 | 127.89 |
| Total Long Term Debt | 17.64 | 107.984 | 145.87 | 130.043 | 120.074 |
| Capital Lease Obligations | 0.782 | ||||
| Other Liabilities, Total | 3.082 | 3.189 | 3.398 | 3.598 | 0.053 |
| Total Equity | -22.264 | -35.071 | -62.812 | -7.379 | 57.375 |
| Preferred Stock - Non Redeemable, Net | 0.004 | 0.004 | 0 | 0 | 0 |
| Common Stock | 0.097 | 0.068 | 0.058 | 0.055 | 0.054 |
| Additional Paid-In Capital | 630.341 | 580.652 | 475.072 | 452.344 | 432.885 |
| Retained Earnings (Accumulated Deficit) | -607.239 | -570.668 | -492.966 | -414.653 | -330.348 |
| Other Equity, Total | -0.4 | -0.06 | 0.091 | -0.058 | -0.149 |
| Total Liabilities & Shareholders’ Equity | 65.015 | 83.047 | 93.425 | 134.424 | 185.265 |
| Total Common Shares Outstanding | 97.4775 | 67.649 | 57.6079 | 54.7088 | 54.2319 |
| Total Inventory | 5.194 | 5.067 | 9.216 | 8.059 | 7.746 |
| Other Long Term Assets, Total | 1.242 | 1.817 | 2.12 | 0.75 | 0.208 |
| Long Term Debt | 16.858 | 107.984 | 145.87 | 130.043 | 120.074 |
| Treasury Stock - Common | -45.067 | -45.067 | -45.067 | -45.067 | -45.067 |
| Total Preferred Shares Outstanding | 3.95455 | 3.95455 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 42.834 | 56.014 | 66.272 | 48.059 | 61.111 |
| Cash and Short Term Investments | 31.865 | 45.561 | 55.394 | 36.772 | 50.376 |
| Cash & Equivalents | 29.408 | 34.905 | 38.987 | 4.581 | 13.654 |
| Short Term Investments | 2.457 | 10.656 | 16.407 | 32.191 | 36.722 |
| Total Receivables, Net | 2.427 | 2.416 | 2.393 | 2.935 | 2.114 |
| Accounts Receivable - Trade, Net | 2.427 | 2.416 | 2.393 | 2.935 | 2.114 |
| Total Inventory | 5.27 | 5.194 | 5.392 | 5.304 | 5.505 |
| Prepaid Expenses | 1.697 | 0.818 | 1.119 | 1.429 | 1.522 |
| Other Current Assets, Total | 1.575 | 2.025 | 1.974 | 1.619 | 1.594 |
| Total Assets | 51.002 | 65.015 | 75.847 | 58.726 | 70.357 |
| Property/Plant/Equipment, Total - Net | 7.073 | 7.759 | 7.952 | 8.816 | 7.455 |
| Property/Plant/Equipment, Total - Gross | 18.208 | 18.58 | 18.772 | 19.816 | 18.338 |
| Accumulated Depreciation, Total | -11.135 | -10.821 | -10.82 | -11 | -10.883 |
| Other Long Term Assets, Total | 1.095 | 1.242 | 1.623 | 1.851 | 1.791 |
| Total Current Liabilities | 68.125 | 66.557 | 66.084 | 66.929 | 113.875 |
| Accounts Payable | 3.524 | 4.501 | 2.819 | 2.221 | 2.717 |
| Accrued Expenses | 6.425 | 3.983 | 5.383 | 7.132 | 4.941 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 57.708 | 57.526 | 57.358 | 57.241 | 105.819 |
| Other Current Liabilities, Total | 0.468 | 0.547 | 0.524 | 0.335 | 0.398 |
| Total Liabilities | 89.727 | 87.279 | 85.835 | 120.69 | 126.413 |
| Total Long Term Debt | 18.135 | 17.64 | 16.997 | 51.007 | 9.541 |
| Long Term Debt | 17.43 | 16.858 | 16.299 | 49.624 | 9.377 |
| Other Liabilities, Total | 3.467 | 3.082 | 2.754 | 2.754 | 2.997 |
| Total Equity | -38.725 | -22.264 | -9.988 | -61.964 | -56.056 |
| Preferred Stock - Non Redeemable, Net | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| Common Stock | 0.1 | 0.097 | 0.097 | 0.08 | 0.069 |
| Additional Paid-In Capital | 630.903 | 630.341 | 627.853 | 560.185 | 547.381 |
| Retained Earnings (Accumulated Deficit) | -624.034 | -607.239 | -592.63 | -576.734 | -558.211 |
| Treasury Stock - Common | -45.067 | -45.067 | -45.067 | -45.067 | -45.067 |
| Other Equity, Total | -0.631 | -0.4 | -0.245 | -0.432 | -0.232 |
| Total Liabilities & Shareholders’ Equity | 51.002 | 65.015 | 75.847 | 58.726 | 70.357 |
| Total Common Shares Outstanding | 99.6283 | 97.4775 | 97.241 | 79.7014 | 68.7116 |
| Total Preferred Shares Outstanding | 3.95455 | 3.95455 | 3.95455 | 3.95455 | 3.95455 |
| Capital Lease Obligations | 0.705 | 0.782 | 0.698 | 1.383 | 0.164 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Cash From Operating Activities | -48.728 | -47.323 | -50.394 | -64.794 | -67.756 |
| Cash From Operating Activities | 3 | 2.518 | 2.997 | 2.602 | 2.561 |
| Amortization | |||||
| Non-Cash Items | 8.512 | 27.963 | 28.162 | 22.997 | 21.328 |
| Changes in Working Capital | 2.253 | -0.102 | -3.345 | -6.088 | -3.319 |
| Cash From Investing Activities | 12.417 | 8.304 | 13.606 | 52.811 | -20.138 |
| Capital Expenditures | -0.554 | -0.603 | -1.362 | -0.33 | -0.998 |
| Other Investing Cash Flow Items, Total | 12.971 | 8.907 | 14.968 | 53.141 | -19.14 |
| Cash From Financing Activities | 31.63 | 43.226 | 11.633 | 6.823 | 125.771 |
| Financing Cash Flow Items | -0.192 | -1.24 | 0 | 0 | -4.992 |
| Issuance (Retirement) of Stock, Net | 33.103 | 44.826 | 6.421 | 6.823 | -40.737 |
| Issuance (Retirement) of Debt, Net | -1.281 | -0.36 | 5.212 | 0 | 171.5 |
| Foreign Exchange Effects | -0.312 | -0.09 | -0.078 | -0.086 | -0.13 |
| Net Change in Cash | -4.993 | 4.117 | -25.233 | -5.246 | 37.747 |
| Cash Taxes Paid | 0 | 0 | 0.043 | 0.041 | 0.651 |
| Cash Interest Paid | 2.214 | 4.288 | 4.288 | 4.288 | 2.001 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -16.795 | -62.493 | -47.884 | -31.988 | -13.465 |
| Cash From Operating Activities | -13.367 | -48.728 | -39.178 | -25.605 | -12.606 |
| Cash From Operating Activities | 0.802 | 3 | 2.207 | 1.435 | 0.616 |
| Non-Cash Items | 1.27 | 8.512 | 5.475 | 4.078 | -0.024 |
| Cash Taxes Paid | 0 | ||||
| Cash Interest Paid | 0 | 2.214 | 2.214 | 1.506 | |
| Changes in Working Capital | 1.356 | 2.253 | 1.024 | 0.87 | 0.267 |
| Cash From Investing Activities | 8.209 | 12.417 | 6.575 | -9.213 | -13.641 |
| Capital Expenditures | -0.012 | -0.554 | -0.446 | -0.447 | -0.447 |
| Other Investing Cash Flow Items, Total | 8.221 | 12.971 | 7.021 | -8.766 | -13.194 |
| Cash From Financing Activities | -0.077 | 31.63 | 31.756 | -0.28 | 0.077 |
| Issuance (Retirement) of Stock, Net | 0 | 33.103 | 33.063 | 0.144 | 0.077 |
| Foreign Exchange Effects | -0.262 | -0.312 | -0.064 | -0.219 | -0.074 |
| Net Change in Cash | -5.497 | -4.993 | -0.911 | -35.317 | -26.244 |
| Issuance (Retirement) of Debt, Net | -0.077 | -1.281 | -1.115 | -0.424 | |
| Financing Cash Flow Items | -0.192 | -0.192 |
Accelerate Diagnostics, Inc. Company profile
About Accelerate Diagnostics Inc
Accelerate Diagnostics, Inc. is an vitro diagnostics company engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Accelerate Diagnostics Inc revenues increased 6% to $11.8M. Net loss decreased 1% to $77.7M. Revenues reflect Foreign segment increase of 93% to $1.7M. Lower net loss reflects Sales, general and administrative - Bala decrease of 9% to $31.6M (expense), Other expense (net) decrease of 67% to $20K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.40 to -$1.26.
Equity composition
Common Stock no Par, 01/11, 14M auth., 10,757,317 issd. Insiders own 31.63%. IPO 11/83, 10M shs @ $.10 by T. Geimer Securities. PO 11/96, 1M shs @ $7 by Janco Partners Inc. 11/96, 1-for-4 reverse stock split. FY'99 Q's are reclassified. *10/03, Exchange change from OTC to AMEX. 1/03 Q is restated.
| Industry: | Advanced Medical Equipment & Technology (NEC) |
3950 S Country Club Rd Ste 470 Bldg 3-307
DENVER
COLORADO 80203
US
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com